Abstract. In the present study we investigated the anti-proliferative activity of 5,7-dimethoxycoumarin on the murine B16 and human A375 melanoma cell lines. The inhibitory concentration 50 (IC₅₀) was estimated for each cell line by preliminary assay of tetrazolium salt reduction (MTT). With Trypan blue exclusion test we detected a cytostatic but not cytotoxic effect of the treatment in melanoma cells: 5,7-dimethoxycoumarin significantly reduced cell proliferation in a time- and dose-dependent manner, blocking the cell cycle in the G₀/G₁ phase both in B16 and A375 cells. Melanoma growth reduction was coupled to a differentiation process detected by monitoring some specific markers: i) morphological changes with development of dendrite-like projections from the cell surface; ii) melanin synthesis; and iii) PpIX accumulation. Induction of the differentiation process was more significant in murine melanoma cells, where the treatment irreversibly reduced cell growth. Consistent with G₀/G₁ arrest and melanogenesis in B16 cells, 5,7-dimethoxycoumarin strongly decreased activation of the mitogen-activated protein kinase extracellular signal-related kinase 1/2, which is upregulated in many types of cancer. These findings suggest that 5,7-dimethoxycoumarin should be further investigated through studies both in vitro, to identify the binding partners for this compound, and in preclinical animal models.

Introduction

Coumarins are a class of compounds widely distributed in plants (1) and showing low toxicity in the human body (2). They possess several biological activities such as anti-bacterial (3), anti-platelet (4,5) vasodilatory (6,7), anti-asthmatic (8), anti-mutagenic (9), and anti-inflammatory (10). They also protect against oxidative damage and exhibit anti-tumourigenic activity (11-14). Coumarins and their derivative compounds have been used in clinical treatment, alone or in combination therapy, of various malignant cancers, such as renal, lung and kidney carcinoma and malignant melanoma (15). Various in vitro data showed antineoplastic activity of these compounds, such as 7-hydroxycoumarin against lung adenocarcinoma and other cell lines (16-19), the synthetic 6-nitro-7-hydroxycoumarin against renal and melanoma cell lines (20-22), esculetin against human leukemia cells (23), decursin against human prostate carcinoma cells (24), and daphnetin against human renal carcinoma cells (22).

A coumarin derivative, 5,7-dimethoxycoumarin, has been identified in a small group of vegetable species, including Euodia borbonica L. var. borbonica (25), Citrus limon L. (26), Citrus bergamia L. (27), Heracleum mantegazzianum L. (28), Citrus medica L. var. sarcodactylis (29) and Carica papaya L. (30). This molecule showed both a differentiating effect on the HL-60 cell line (27) and an inhibition activity in DNA adduct formation, induced by carcinogens, in mouse mammary gland (31).

The differentiation process still represents a crucial point in development and progression of many cancer types, such as melanoma, which show also alterations in the normal cell growth program and survival time (32). In such a scenario mitogen-activated protein kinases (MAPKs, serine threonine kinases) seem to play an important role by Ras/Raf/MEK/ERK pathway controlling cellular processes such as differentiation, proliferation and death (33). Moreover, some proto-oncogenes, involved in tumor development and progression, encode proteins of the Ras/Raf/MEK/ERK pathway which are constitutively activated in the growth process of several types of cancer (34).

Since research in melanoma cancer therapy is focused on the discovery of novel drugs able to reduce its proliferative capacity and induce terminal differentiation (35), in this study we have investigated the antiproliferative activity of 5,7-dimethoxycoumarin in murine B16 and human A375 melanoma cell lines, specific markers of melanoma cell
differentiation and the expression level of extracellular signal-related kinase (ERK) 1/2 after treatment.

Materials and methods

Test compound. Synthetic 5,7-dimethoxycoumarin was purchased from Sigma-Aldrich (116238). The compound was dissolved in methanol and a concentration of 20 mM was obtained. In the treatment of cells, a volume of this solution was added to culture medium and its percentage with respect to the medium was 0.5, 1.25 and 2.5% for 100, 250 and 500 μM, respectively.

Cell lines and culture conditions. Cell lines used in this study were murine melanoma B16 F1, human melanoma A375, human breast adenocarcinoma MCF7, human prostate adenocarcinoma PC3, and human colorectal carcinoma SW620. Cancer cell lines were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). As control, non-neoplastic murine cardiofibroblasts and human foreskin fibroblasts were used. Cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS), 1% L-glutamine (v/v), 100 units/ml penicillin and 100 μg/ml streptomycin. The cells were grown at 37˚C in a humidified atmosphere with 5% CO₂.

MTT assay. 5,7-dimethoxycoumarin activity on cell growth was estimated by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay, that is based on the cleavage of the yellow tetrazolium salt to purple formazan crystals by intracellular dehydrogenases (36). Briefly, 1-2x10⁶ cells/well were seeded into sterile 96-well plates. After 24 h, 5,7-dimethoxycoumarin was added to cell culture medium over a final concentration range of 0-500 μM and the cells were incubated at 37˚C in 5% CO₂ for a period of 24-72 h. After the incubation period, MTT (Sigma-Aldrich) was added to each well and incubated for a further 4 h. Then, medium was removed, blue crystals of MTT reduced by cells were dissolved with DMSO and fluorescent signal was measured: scattering properties and fluorescence emitted from the cells at 670 nm were collected and analysed.

Trypan blue exclusion test. B16, A375 and SW620 cells were seeded and treated as described above. After 24-, 48- and 72-h incubation at 37°C in 5% CO₂, cells were washed, harvested, pelleted and stained with propidium iodide (PI) staining solution containing 50 μg/ml PI, 0.5% RNase A and 0.1% Triton X-100. After incubation for 30 min at 4°C in the dark, cell cycle distributions were analyzed by flow cytometry on a FACScalibur (Becton Dickinson, Mountain View, CA). Using CellQuest Pro software, the percentage of cells at different phases of the cell cycle was determined. PI was excited at 488 nm, and fluorescence analyzed at 620 nm. A total of 10,000 events in each sample were acquired.

Protoporphyrine IX (PpIX) analysis and phenotypic characterization with flow cytometry. B16, A375 and SW620 were seeded at a density of 1-1.5x10⁶ cells/ml in 24-well plates. After 24 h cells were treated with methanol or 100, 250 and 500 μM 5,7-dimethoxycoumarin. After 24-, 48- and 72-h incubation at 37°C in 5% CO₂, cells were washed with PBS, harvested by trypsinization, pelleted and resuspended in PBS. After treatment, cells were washed several times with PBS and digested by trypsinization and mixed with the corresponding floating cells in the medium of each well were transferred to centrifuge tubes; adherent cells were washed, collected by trypsinization, pelleted, washed twice with PBS and digested by trypsinization, pelleted, washed twice with PBS and digested by trypsinization. Cells were stained with 0.4% trypan blue and counted in triplicate with an optic microscope with the aim to estimate the number of live and dead cells. Cell viability was expressed as a percentage of treated cells with respect to appropriate vehicle-treated controls, and toxicity as a percentage of dead cells with respect to the total number of cells. Moreover, B16 cells treated for 72 h were washed and reseeded in fresh medium at 1x10⁶ cells/well without the compound. After 48-, 72- and 96-h incubation at 37°C in 5% CO₂, the irreversible or reversible growth inhibitory effect of the compound was observed by trypan blue test.

The B16 and A375 treated cells were observed with an inverted microscope and photographed at x10 and x20 with a Nikon Coolpix 995 digital camera to detect any drug-induced morphological changes.

Cell cycle analysis. B16 and A375 cells were seeded and treated as described above. After 24-, 48- and 72-h incubation at 37°C in 5% CO₂, cells were washed, harvested, pelleted and stained with propidium iodide (PI) staining solution containing 50 μg/ml PI, 0.5% RNase A and 0.1% Triton X-100. After incubation for 30 min at 4°C in the dark, cell cycle distributions were analyzed by flow cytometry on a FACScalibur (Becton Dickinson, Mountain View, CA). Using CellQuest Pro software, the percentage of cells at different phases of the cell cycle was determined. PI was excited at 488 nm, and fluorescence analyzed at 620 nm. A total of 10,000 events in each sample were acquired.

Melanin synthesis in B16 cells. B16 cells were seeded and treated as reported above, in order to measure extracellular and intracellular melanin according to the method of Hill et al (37). After 72-h incubation at 37°C in 5% CO₂, the culture medium was removed, centrifuged (700 x g, 10 min) and the supernatant was collected for extracellular melanin quantification; 1 ml of 0.4 M HEPES buffer (pH 6.8) and EOH (9:1, v/v) was added to 1 ml of the medium and the OD at 475 nm was measured to quantify extracellular melanin by using a calibration curve obtained with synthetic melanin solutions. Cells were collected by trypsinization, pelleted, washed twice with PBS and digested in 1 ml 1 N NaOH for 16 h at room temperature; intracellular melanin was measured as described above. The stimulation of melanogenesis following the treatment was estimated as percentage of total melanin (μg/ml) calculated by the addition of intracellular and extracellular melanin, synthesized in treated cells with respect to vehicle-treated controls.

Western blot analyses. B16 cells were seeded and treated as described above. After a 72-h treatment time, cells were washed, collected by trypsinization and suspended in RIPA lysis buffer [1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 0.15 NaCl, 0.01 M sodium phosphate, (pH 7.2), 2 mM EDTA, 50 mM sodium fluoride, 0.2 mM sodium vanadate and 100 units/ml aprotinin]. After 1 h on ice, the
cell lysates were cleared by centrifugation at 13000 \times g for 15 min and the resultant supernatants collected and used for Bradford (38) assay to estimate protein concentration. Then, 100 \mu g of total protein lysates were resolved on 12% sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE) and the separated proteins were transferred to PVDF membrane. The level of MAPK expression in each sample was detected using mouse monoclonal primary antibody against phospho-ERK 1/2 (Tyr-204), diluted 1:250 in TTBS solution containing 1\%(w/v) of BSA, followed by peroxidase-conjugated goat anti-mouse secondary antibody and enhanced chemiluminescence visualization. Membranes were stripped and reprobed with \alpha-tubulin primary antibody as a protein loading control. The antibodies and detection system were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

**Statistical analysis.** Student's t-test was employed to determine the significance of any reduction in cellular viability, the increase of melanin synthesis and any alteration in cell cycle following the treatment. A probability of \leq 0.05 was deemed statistically significant.

**Results**

*5,7-dimethoxycoumarin reduces the metabolic activity of murine and human cell lines.* In the first set of experiments, the anti-neoplastic activity of 5,7-dimethoxycoumarin in both murine and human cell lines of melanoma was measured using MTT assay in basic culture conditions for each cell line, to evaluate any level of cell growth. As control, we also evaluated the effect of the compound in various human adenocarcinoma
The compound significantly reduced metabolic activity, in a dose-dependent manner up to 70% after 72-h treatment with respect to the control. The concentration of 100 μM did not show a significant growth inhibition activity, except for B16, PC3 and MCF7 lines. The concentrations of 250 and 500 μM significantly inhibited cellular proliferation in each incubation time for every cell line (Fig. 1). In Table I, IC50 values, estimated after 72 h of treatment, are reported and evidence that 5,7-dimethoxycoumarin exhibited a clear effect not only in melanoma but also in adenocarcinoma cell lines.

Effect of 5,7-dimethoxycoumarin on the growth and death of melanoma cell lines. MTT assay did not reveal if the reduction of proliferation was related to growth arrest or cell death since both mechanisms could result in reduced cell numbers and an apparent loss of viability. To establish that, a trypan blue exclusion test was carried out on melanoma cell lines. The results reported in Fig. 2A show that 5,7-dimethoxycoumarin possessed an antiproliferative activity on B16 cell growth at all the concentrations tested. The compound inhibited the growth of B16 cells significantly, as compared with the control group, at 48 and 72 h, accounting for 35-47%, 48-68% and 61-72% inhibition, at the doses of 100, 250 and 500 μM, respectively. The inhibitory effect was time- and dose-dependent.

In the same way, the treatment with 5,7-dimethoxycoumarin significantly reduced the proliferation of A375 cells (Fig. 2B), accounting for 0-45%, 17-68% and 41-80% of reduction at the doses of 100, 250 and 500 μM, respectively. The inhibition of cell growth was significant with respect to the control in each treatment time, except for the concentration of 100 μM at 24 h. The inhibitory effect was time- and dose-dependent.

IC50 values at 72 h were obtained also through trypan blue test and they accounted for 109 and 142 μM in B16 and A375, respectively (Table I). Interestingly, they were lower than those derived from MTT assay at the same time of treatment. That probably is a consequence of the lower reliability of an indirect assay, such as MTT assay, compared to a direct one such as the trypan blue test (39).

Moreover, the effect of the compound on murine melanoma cells was long lasting, since the same cells previously treated at doses of 100, 250, and 500 μM, washed, reseeded and cultured without treatment, showed a significant reduced performance of proliferation with respect to untreated cells. After 96 h of incubation at 37˚C in 5% CO2, the growth reduction produced by previous treatment was 42%, 61% and 57% at the doses of 100, 250 and 500 μM, respectively. Statistical differences were observed between the values obtained with 100 and 250 μM doses, and with 100 and 500 μM doses (Fig. 2C). These results evidenced that the antiproliferative effect of the compound was irreversible since

**Table I. IC50 of 5,7-dimethoxycoumarin in different cell lines following 72-h treatment.**

<table>
<thead>
<tr>
<th>Histological type</th>
<th>Cell line</th>
<th>IC50 (μM)</th>
<th>IC50 (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human melanoma</td>
<td>A375</td>
<td>300</td>
<td>142</td>
</tr>
<tr>
<td>Murine melanoma</td>
<td>B16</td>
<td>260</td>
<td>109</td>
</tr>
<tr>
<td>Human adenocarcinoma</td>
<td>MCF7</td>
<td>250</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>PC3</td>
<td>285</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>SW620</td>
<td>325</td>
<td>-</td>
</tr>
</tbody>
</table>

*Cells were incubated with or without the compound using 100-, 250- and 500-μM doses; then, MTT assay and trypan blue exclusion test were carried out, as described in Materials and methods. A graph of viability versus drug concentration was used to calculate IC50 values for each cell line. IC50 values as obtained by MTT assay. IC50 values as obtained by trypan blue exclusion test.
proliferation did not return to control levels even at the end of the 96-h recovery period.

The percentage of dead cells calculated as explained in the Materials and methods sections, after treatments for both cell lines was also evaluated. No significant cytotoxicity was observed at any experimental time and dose with respect to the control (data not shown).

5,7-Dimethoxycoumarin did not change significantly the growth of non-neoplastic cardiofibroblasts for any of the used concentrations (data not shown).

5,7-Dimethoxycoumarin blocks the cycle of melanoma cells in the G0/G1 phase. Since the strong inhibitory effect induced by 5,7-dimethoxycoumarin could be related with a decrease of DNA synthesis, we then investigated its effect on cell cycle events. After treatment, we demonstrated by FACS analysis, that 5,7-dimethoxycoumarin induced a strong and dose-dependent arrest of cell cycle progression in the G0/G1 phase in B16 and A375 cell lines, when compared with the control sample, with reduction of S and G2/M phase population. In regard to B16 cells (Fig. 3), the accumulation in the G0/G1 after 24-h phase was significant at high dose and consistent with growth arrest when compared to the control. An accumulation of melanoma cells in the G0/G1 phase was detected also after 48- and 72-h treatment, although the differences with respect to the control were less significant than after 24 h of incubation (data not shown). Moreover, after 72 h of treatment the dose of 500 μM induced an accumulation of B16 cells in the sub-G1 phase of ~10% (data not shown). Similarly, in A375 cells, a G0/G1 arrest was observed at the 500-μM dose after 24 h (data not shown), which did not change at later treatment times. However, 250-μM dose of 5,7-dimethoxycoumarin showed a significant increase after 48-h treatment (Fig. 4).

Morphological effects of 5,7-dimethoxycoumarin in melanoma cells. Since the treatment with 5,7-dimethoxycoumarin showed low cytotoxicity, we hypothesised that growth inhibition was due to the induction of a differentiation process that is generally coupled to a block in cellular proliferation (40,41). To verify this hypothesis first we evaluated the morphology of melanoma cell lines after treatment under an inverted microscope. B16 cell analysis by digital images (Fig. 5) showed a dose-dependent decrease of cellular density in the culture treated with different doses of 5,7-dimethoxycoumarin, according to the results obtained with the trypan blue test. Moreover, a clear morphological change was detected in cells, since the treatment induced the formation of dendrite-like projections which gave a star-like shape to the cells compared to rounded untreated cells. This effect was more evident with the increase of treatment time and concentration and after 5,7-dimethoxycoumarin washout it did not recover the control morphology (data not shown). Similar results were obtained for A375 cells regarding cellular density, but generally morphological changes were less evident than those obtained in B16 cells (data not shown).
5,7-Dimethoxycoumarin increased PpIX accumulation and altered phenotypic characteristics in melanoma cells. Cellular differentiation has been related to an increase of intracellular PpIX accumulation for some cancer cell lines including B16 cells (42,43). To investigate if the treatment with 5,7-dimethoxycoumarin induced a significant augmentation in PpIX production, melanoma cell lines were treated with doses of 100, 250 and 500 μM for 72 h. As shown in Fig. 6, PpIX accumulation was enhanced following an increase of the dose of tested compound for both B16 (Fig. 6A) and A375 (Fig. 6B) cell lines. After 72-h incubation at the higher concentration of 5,7-dimethoxycoumarin used, the increase of PpIX was 3.3-fold (B16) and 1.6-fold (A375) with respect to the control. Instead, in SW620 cells, used as control, accumulation of PpIX was unchanged after treatment in the same experimental conditions (data not shown).

Further phenotypic alterations were observed through cytofluorometric analysis of both treated melanoma cell lines. A change in light scatter properties of B16 and A375 cells treated with 5,7-dimethoxycoumarin was detected. In particular, a decrease of FSC (forward scatter) mean values with respect to the solvent control was observed; at the same time, SSC (side scatter) mean values increased strongly following the treatment. This effect was more pronounced in B16 than A375 cells. In Fig. 7 results relative to the treatment with a 500-μM dose for 72 h are shown. These effects were time- and dose-dependent (data not shown). Also phenotypic characterization of SW620 cells was carried out, but changes in FSC and SSC were not detected after treatment, using the same experimental conditions (data not shown).

The melanogenesis process was induced in B16 cells following treatment with 5,7-dimethoxycoumarin. Since the changes in
light scatter properties of B16 and A375 cells could be related to an increase of cellular complexity, we further investigated the melanogenesis process in B16 cells, where the changes in light scatter properties were more evident compared to the A375 cells. After 72-h incubation, 5,7-dimethoxycoumarin was demonstrated to induce melanin synthesis in B16 treated cells as shown in Fig. 8. Both the extracellular and intracellular melanin quantity significantly increased with respect to the control for all tested doses. Total melanin calculation revealed that the melanogenesis was significantly increased in a dose-dependent manner by approximately 2.12-, 3.0-, and 3.55-fold with respect to the control for 100, 250 and 500 μM 5,7-dimethoxycoumarin, respectively. These results also demonstrated that 5,7-dimethoxycoumarin induced a differentiation program in B16 cells since stimulation of melanogenesis is considered a well-known marker of differentiation for melanoma cells (44).

Effects of 5,7-dimethoxycoumarin on ERK 1/2 activation. To unravel the potential mechanism underlying 5,7-dimethoxycoumarin-induced effects, inhibition of cell growth and stimulation of the differentiation process, we examined the alterations in activation of a MAPK signalling pathway following treatment. The effects of 5,7-dimethoxycoumarin on ERK 1/2 phosphorylation in the B16 cell line after 72-h treatment are shown in Fig. 9A. The treatment of B16 cells with 5,7-dimethoxycoumarin inhibited the activation of the protein in a dose-dependent manner resulting in a moderate to complete inhibition. Densitometric analysis allowed us to calculate the treatment effect, with respect to the methanol control, in phospho-ERK (p-ERK) expression: the reduction of p-ERK 1/2 expression was 60%, 85% and 96% for 100, 250 and 500 μM, respectively (Fig. 9B).

Discussion

Among the biological properties possessed by coumarins, one that makes these compounds attractive is the antitumour activity showed by some members of this chemical group. In particular, 5,7-dimethoxycoumarin, a coumarin derivative identified in a few vegetable species and recently also in Carica papaya (30), was the object of our investigation since it has been scarcely studied up to now. We decided to test the antitumour efficacy of this compound on different cancer cell lines in vitro by using first MTT assay, widely used for high through-put screening of new drugs. Our results indicated that 5,7-dimethoxycoumarin inhibited the growth of several cell lines, of melanoma and carcinoma origin, in a comparable manner; our data showed that the effect was not species- or line-specific. Since MTT is an indirect colourimetric assay, the trypan blue test was then used to directly assess the cell survival rate in melanoma lines following treatment. Antineoplastic activity of the molecule was confirmed, but IC_{50} values obtained after a 72-h treatment were considerably lower than those from the MTT test. This discrepancy in test sensitivity could be explained considering that MTT assay is based on intracellular dehydrogenases whose activity could be altered by the tested compound (45). Not shown results allowed us to exclude the feasibility of a direct MTT reduction by 5,7-dimethoxycoumarin. By direct cell counting it is possible to distinguish between cytostatic and cytotoxic effect; in this case, our results indicated a cytostatic activity exerted by this molecule, at least in the experimental conditions used. However, we can not rule out that higher doses and longer incubation times could exert cytotoxic activity, since our experimental observations were extended for up to 72 h of culture and at a maximum dosage of 500 μM in the presence of 5,7-dimethoxycoumarin.

FACS analysis demonstrated that 5,7-dimethoxycoumarin caused an arrest of the cell cycle in the G_{0}/G_{1} phase with a decrease of cell population in synthesis and mitosis phases in melanoma cells. Other coumarins with anticancer properties blocked the cell cycle either in the G_{0}/G_{1} phase (18) or in the S phase (22). Since most of the antineoplastic drugs in clinical use block the cell cycle in the S or G_{2}/M phases whereas 5,7-dimethoxycoumarin blocks the cell cycle in the G_{1} phase, a combination of 5,7-dimethoxycoumarin with currently used drugs might possibly improve therapies of melanoma. Moreover, cytostatic activity proved irreversible by culturing the B16 cells, previously treated, without the compound; after some days of culture in fresh medium the treated cells did not recover control growth. Generally, an irreversible growth inhibition is determined by either apoptotic cell death or differentiation process (46). In B16 cells following treatment with 5,7-dimethoxycoumarin, we observed significant morphological changes and characteristic markers specific of melanoma cell differentiation. In fact, following incubation, B16 cells gained a star-like shape with dendritic projections. Morphological alterations were also revealed through flow cytometry analysis. Treated melanoma cells exhibited subtle reduction of FSC compared to the control, indicating that the incident light was absorbed rather than transmitted through the cells presumably due to an augmentation of light absorbing melanin. However, we can not rule out the possibility that
such changes could be due to cell size reduction or to the presence of other cellular components that absorb incident light. On the contrary, we observed a high increase of SSC that generally indicates the granularity of a cell, in melanoma treated cells, especially in the B16 cell line, after treatment with 5,7-dimethoxycoumarin. We hypothesised that this reflects an increase of intracellular number of melanosomes, supported by the evidence that SW620, a human adenocarcinoma cell line, did not change light scatter properties after treatment with the compound.

Based on these data, we investigated the melanin content in B16 cells, where the effect of the 5,7-dimethoxycoumarin on light scatter properties was more evident. An augmentation in melanin synthesis was observed in treated cells, as hypothesised above. Morphological changes with dendrite outgrowth and melanogenesis are considered specific markers of differentiation for B16 cells (40).

It is well known that some melanoma differentiation agents, such as UV-B (47) and cyclic adenosine monophosphate (cAMP) (48), stimulate dendriticity and melanogenesis after blocking cells in the G0/G1 phase as well as our tested compound.

We suggested that 5,7-dimethoxycoumarin induced a terminal differentiation in B16 cells that eventually causes cell death, even if the ultimate fate of the growth arrested cells was not analysed. This hypothesis is supported by the observation that exposure to the highest dose of compound for 72 h led to a small accumulation of cells in the sub-G1 phase; moreover, the compound irreversibly induced both cell growth inhibition and morphological changes. A less significant change in cellular shape was observed also in the treated A375 cell line. It has been reported that novobiocin, a coumarin derivative with antibiotic properties, inhibited B16 cell proliferation, but not in a reversible manner, and induced cellular differentiation (49). Recently, novel synthetic nitrocoumarins, namely 6-nitro-7-hydroxy-coumarin and 3,6,8-trinitro-7-hydroxycoumarin have been shown to be anti-proliferative and differentiation agents in human melanoma cells (50).

As a further marker of differentiation we monitored the production of PpIX, a photosensitiser compound synthesized and localized in the mitochondria as intermediate molecules in the heme biosynthesis pathway, of which 5-aminolevulinic acid (ALA) is the first intermediate. The treated melanoma cells emitted a PpIX fluorescence higher than untreated cells owing to a synthesis increase and intracellular accumulation of PpIX during treatment (51). It has been reported that the induction of differentiation enhanced PpIX accumulation in some cell lines, such as prostate cancer cells (51), fibroblasts, B16 cells (42) and keratinocytes (52). However, the relationship between tumour cell differentiation and photosensitizer accumulation is poorly defined (53) since some differentiation agents, such as butyrate, did not enhance PpIX accumulation whereas others, such as hexamethylene bisacetamide (HMBA) and methotrexate, did (43,54). To the best of our knowledge, this is the first evidence that a member of the coumarin group enhanced PpIX accumulation at least in melanoma cells; this observation was not reproduced in SW620 cells suggesting a cell-type specific effect. PpIX production is exploited clinically in photodynamic therapy of cancer (PDT), accepted in the care of superficial epithelial neoplasias. This therapy uses ALA, an inert pharmacological precursor that remains inactive until it is converted into a photosensitising agent (PpIX) that is activated by light to generate reactive oxygen species (ROS), leading to cancer cell death via necrosis or apoptosis (55). A combination therapy using a differentiation agent that specifically enhances PpIX production in cancer cells and PpIX precursor could be very useful, because tumour eradication with ALA-PDT is not always obtained. Based on this premise, our data are particularly interesting, although more studies are needed to establish the interaction between 5,7-dimethoxycoumarin and ALA-PDT.

With the aim to elucidate the mechanism by which 5,7-dimethoxycoumarin reduced proliferation and induced differentiation in treated B16 cells, we focused our attention on the phosphorylation status of ERK 1/2 following treatment. ERK 1/2 (extracellular signal-regulated kinase) is a member of the Ras/Raf/Mek/ERK mitogen-activated protein kinase (MAPK) signalling pathway that regulates cell survival, proliferation and differentiation processes following transmission of a wide variety of extracellular stimuli from the cell surface to the nucleus (56). Its phosphorylation by MEK 1/2 in serum and threonine residues activates a series of transcription factors in the nucleus, such as c-Myc, NF-IL6 and Elk-1, initiating the transcription of genes encoding for proteins that promote cell cycle progression through $G_0/G_1$ phase and from $G_1/S$ phase, such as the cyclins D and E, and then cell proliferation (56,57). Using Western blot analysis, we detected a reduction in the phosphorylation of ERK 1/2, following incubation of B16 cells with 5,7-dimethoxycoumarin; the inhibition of the MAPK activation was more evident with an increase of tested compound concentration and this data was comparable with cell cycle analysis and trypan blue assay results, since reduction of ERK phosphorylation by the treatment caused the block in the $G_0/G_1$ phase and subsequently growth reduction and differentiation. It has been reported that Ras/Raf/MEK/ERK pathway is constitutively activated, following mutation in the catalytic domain of these protein kinases, in a high percentage of human melanoma cells; particularly, an activating mutation of B-Raf that induces a constitutive phosphorylation of ERK has been detected in 66% of human melanomas (58). It is known that the treatment of melanoma cells with either U0126 (MEK 1 inhibitor) or PD098059 (MEK 2 inhibitor) causes an inhibition of cell growth and a reduction in levels of matrix metalloproteinases MMP-1 and MMP-2; involved in tumor cell invasion, demonstrating that activation of ERK is an important event in melanoma development (58). Based on this assumption, the MAPKs of Ras/Raf/MEK/ERK signalling pathway are considered key molecular targets of novel therapy in melanoma cancer research and several agents that target this pathway are already undergoing clinical testing (59). Therefore, we should further investigate if 5,7-dimethoxycoumarin reduces ERK 1/2 activation by inhibition of catalytic activity of upstream kinases to define the therapeautic potential of the compound.

The microphthalmia-associated transcription factor (Mitf) is another substrate regulated by p-ERK 1/2 and it is involved in differentiation, proliferation and survival of melanocytes (60,61). It activates the transcription of the gene encoding for tyrosinase, which catalyses the hydroxylation of L-tyrosine...
to L-3,4-dihydroxyphenylalanine (L-DOPA) followed by the oxidation of L-DOPA to dopaquinone, two key steps in the pathway of melanin synthesis (62). It is known that the MAPKs play a key role in tyrosine expression and the melanogenesis process; particularly, p-ERK 1/2 downregulates Mitf by phosphorylation at serine 73 and subsequent degradation. Furthermore, Englaro et al (63) observed that inhibition of Ras/Raf/MEK/ERK MAPK pathway led to the B16 cell differentiation and melanogenesis increasing tyrosinase expression and activity. During melanogenesis induced by some agents, including α-melanocyte stimulating hormone (α-MSH) and forskolin, the Mitf transcriptional activity is regulated through the cAMP-mediated pathway with the activity of protein kinase A (PKA) that upregulates the Mitf gene transcription by phosphorylation of the transcriptional factor CREB (cAMP-response element-binding protein) (64). Also PpIX induces melanogenesis through the cAMP-mediated pathway activating the soluble guanylate cyclase and elevating intracellular cGMP (cyclic guanine monophosphate) content (65), which was demonstrated to increase cAMP content by inhibition of cAMP phosphodiesterase (66). In our study, during melanogenesis induced by 5,7-dimethoxycoumarin in B16 cells, we observed a dephosphorylation of MAPK ERK 1/2, in agreement with previous studies, and an intracellular accumulation of PpIX. Therefore, induction of melanogenesis in treated B16 cells could be regulated through both Ras/Raf/MEK/ERK MAP kinase and cAMP-mediated pathways.

This study showed the in vitro anticancer activity of 5,7-dimethoxycoumarin in melanoma cells through cell cycle arrest and differentiation induction. Furthermore, cell growth of non-neoplastic cardiofibroblasts was not modified significantly by the treatment suggesting a selective antiproliferative effect of the compound in cancer cell lines. These findings should be developed with in vivo studies in preclinical animal models. The antiextracellular accumulation of PpIX. Therefore, induction of melanogenesis in treated B16 cells could be regulated through both Ras/Raf/MEK/ERK MAP kinase and cAMP-mediated pathways.

**Acknowledgements**

We are grateful to Dr Di Nardo for murine cardiofibroblasts.

**References**


